NEW YORK, November 13, 2025 – Immunic, Inc. ( Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback